RE: The recent seller...11 Aug 2021 20:52
"The ImmunoINSIGHTS pipeline of qualified commercial opportunities has continued to grow throughout FY21 and currently stands at more than 160. A number of these opportunities are in late stage legal documentation and, as a consequence, the Company expects to sign these new contracts in Q1 FY22. These studies have been programmed into the Company's forward production schedule, which entails identifying and assigning the resources required to deliver each contract. Of particular note in this schedule are two contracts for major pharmaceutical companies which represent substantial follow-on validation contracts.
The anticipated signing of these new contracts in Q1 FY22 together with those contracts already signed in FY21 is expected to deliver revenue of approximately 50% of the FY22 market expectations for the ImmunoINSIGHTS business. With this high degree of visibility of revenue at the beginning of the financial year, we are confident in the Group's ability to deliver management's revenue expectations for FY22."
the Company expects to sign these new contracts in Q1 FY22. - News this month
The anticipated signing of these new contracts in Q1 FY22 - We should expect news this month, new contracts.
May be some news on US listing.
It's good to see we've quitley moved from 155 region to 180s - 190.
I can see it break £2 before news, probably at the end of this month.